Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates

B. N. Doebbeling, M. A. Pfaller, M. J. Bale, R. P. Wenzel

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

The in vitro activity of sparfloxacin (CI-978, AT-4140), a new quinolone which is active against gram-negative and gram-positive bacteria, and nine other broad-spectrum antibiotics was tested against 128 gram-negative nosocomial bloodstream isolates from separate patients. Sparfloxacin and ciprofloxacin were among the most potent antibiotics against Escherichia coli (n=40), Enterobacter cloacae (n=18), Klebsiella oxytoca (n=13), and Klebsiella pneumoniae (n=19), with MIC90 values of ≤ 0.25 μg/ml. Ciprofloxacin was slightly more potent than sparfloxacin against Serratia marcescens (n=14), the MIC90 values being 0.25 and 1.0 μg/ml respectively, although all strains were susceptible to both agents. Sparfloxacin was slightly less potent than ciprofloxacin against Pseudomonas aeruginosa (n=24), the MIC90 values being 4.0 and 0.5 μg/ml respectively. Overall, the in vitro activity of sparfloxacin compared favorably with that of ciprofloxacin and the other broad spectrum agents tested against nosocomial gram-negative bloodstream isolates.

Original languageEnglish (US)
Pages (from-to)298-301
Number of pages4
JournalEuropean Journal of Clinical Microbiology & Infectious Diseases
Volume9
Issue number4
DOIs
StatePublished - Apr 1 1990
Externally publishedYes

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates'. Together they form a unique fingerprint.

  • Cite this